|
|
|
|
|
|
|
Highlights from the 2025 Society of Urologic Oncology Annual Meeting |
|
|
|
|
| Community Social Vulnerability and Clinical Risk-Based Care Implementation for Black Men with Prostate Cancer Treated in Community Settings
|
| Jason L. Goodloe, MD
|
| Jason Goodloe presented an analysis evaluating how race and community-level social vulnerability influence risk-based prostate cancer treatment patterns and metastasis-free survival in community settings.
|
|
|
|
|
|
| Comparison of PSA Response Among Patients with mCSPC Treated with Apalutamide or Abiraterone Acetate – A Real-World Study
|
| Benjamin Lowentritt, MD, FACS
|
| Benjamin Lowentritt presented a large real-world analysis comparing apalutamide versus abiraterone acetate for mCSPC, showing that apalutamide produced significantly higher and faster PSA90 responses within 6 months. Apalutamide also achieved PSA90 in less than half the time, even after robust adjustment for baseline differences.
|
|
|
|
|
|
| Real-World Assessment of New-Onset Central Nervous System Conditions in Patients with nmCRPC Treated with Apalutamide, Darolutamide, or Enzalutamide
|
| Charmi Patel, MD
|
| This large real-world study compared new-onset CNS side effects in men with nmCRPC treated with apalutamide, darolutamide, or enzalutamide using linked EMR and claims data. Apalutamide showed the lowest incidence and longest time-to-onset of CNS events, darolutamide showed intermediate rates, and enzalutamide had the highest and earliest CNS toxicities.
|
|
|
|
|
|
| PROSTest, a Novel Blood-Based mRNA Assay, Can Accurately Predict Outcomes to 177Lu-PSMA in Metastatic Castration-Resistant Prostate Cancer
|
| Mark Kidd, PhD
|
| Mark Kidd presented data on PROSTest, a novel blood-based mRNA assay designed to predict response to 177Lu-PSMA radioligand therapy in mCRPC. In a multi-center cohort of 268 patients, a decrease in PROSTest score after one treatment cycle strongly correlated with improved progression-free and overall survival, with 90% of clinical responders showing an early score drop.
|
|
|
|
|
|
| IDeate-Prostate02: A Phase 1/2 Open-label Umbrella Substudy of Ifinatamab Deruxtecan-based Treatment Combinations or as Monotherapy in Participants with Previously Treated mCRPC
|
| Fariba Jafari, PhD |
| Fariba Jafari presented IDeate-Prostate02, a global phase 1/2 umbrella trial evaluating the B7-H3–targeted ADC ifinatamab deruxtecan (I-DXd) as monotherapy or in combination with docetaxel, opevesostat, abiraterone, or enzalutamide in previously treated mCRPC. The study aims to define safety, optimal dosing, and early efficacy—particularly PSA50 response—across ~360 participants stratified by B7-H3 expression and metastatic pattern.
|
|
|
|
|
|
|
|
|
|
|
| CYP11A1 Inhibitor Opevesostat Alone or in Combination with Other Therapies for Participants with Metastatic Castration-resistant Prostate Cancer: The Phase 1/2 OMAHA-01A Substudy
|
| Arif Hussain, MD
|
| OMAHA-01A is a global phase 1/2 study evaluating opevesostat (MK-5684), a first-in-class CYP11A1 inhibitor that blocks steroidogenesis upstream of all androgen pathways, as monotherapy or combined with olaparib, docetaxel, or cabazitaxel in men with mCRPC. The trial aims to characterize safety, pharmacodynamics, PSA responses, and early antitumor activity across multiple therapeutic contexts.
|
|
|
|
|
|
| Effective Resolution of Bone Metastases in Patients with Metastatic Prostate Cancer Using SYNC-T Therapy SV-102
|
| Gerald L. Andriole, Jr., MD
|
| SYNC-T Therapy SV-102, a minimally invasive intratumoral immunotherapy combining partial oncolysis with a four-agent biologic, demonstrated an 87% overall response rate in 15 patients with metastatic prostate cancer, including complete resolution of bone metastases in 54% of evaluable patients. Responses were rapid and durable, with an overall favorable safety profile dominated by low-grade adverse events.
|
|
|
|
|
|
| PSMAndARPI: Phase II Study of 177Lu-PSMA-617 Plus Androgen Receptor Pathway Inhibitor versus 177Lu-PSMA-617 as First-line Treatment of PSMA-positive Progressive mCRPC
|
| Diego Ospina Gonzalez
|
| Diego Ospina Gonzalez presented PSMAndARPI, a phase II trial testing whether combining ¹⁷⁷Lu-PSMA-617 with an ARPI (abiraterone or enzalutamide) improves first-line outcomes in PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) compared with ¹⁷⁷Lu-PSMA-617 alone. The study is based on strong biologic rationale that radioligand-induced DNA damage may sensitize tumors to AR blockade, and its primary endpoint is radiographic progression-free survival assessed by centralized review. |
|
|
|
|
|
|
|
|
|
|
| ProstACT Global: A Phase 3 Study of Lutetium Rosopatamab Tetraxetan Plus Standard of Care versus Standard of Care Alone in Patients with Metastatic Castration-Resistant Prostate Cancer
|
| Denise Guibault
|
| ProstACT Global is a multinational phase III trial evaluating ¹⁷⁷Lu-rosopatamab, a PSMA-targeted radioimmunotherapy, plus standard of care versus standard of care alone in patients with PSMA-positive mCRPC who previously received an ARPI and taxane. The study includes a safety/dosimetry lead-in followed by a large randomized phase comparing two fixed doses of ¹⁷⁷Lu-rosopatamab given 14 days apart.
|
|
|
|
|
|
| IDeate-Prostate01: A Phase 3, Randomized, Open-Label Study of Ifinatamab Deruxtecan vs Docetaxel in Participants with Previously Treated mCRPC
|
| Rana McKay, MD
|
| IDeate-Prostate01 is a global phase 3 trial comparing the B7-H3–targeted antibody–drug conjugate ifinatamab deruxtecan (I-DXd) with docetaxel in men with previously treated metastatic castration-resistant prostate cancer. Building on promising early data, the study will enroll ~1,440 patients who previously received 1–2 ARPIs, with overall survival and radiographic progression-free survival as dual primary endpoints.
|
|
|
|
|
|
| Efficacy of Rucaparib vs Physician’s Choice in Patients with BRCA-Mutated mCRPC by Age: Results from the TRITON3 Study
|
| Alan Bryce, MD
|
| Age-stratified analysis of the TRITON3 trial showed that rucaparib significantly improved radiographic progression-free survival versus physician’s choice in BRCA-mutated mCRPC across all age groups, including patients ≥75 years and even those ≥81 years. Median rPFS with rucaparib was consistently 11.2 months versus 5.4–7.6 months with physician’s choice, with hazard ratios favoring rucaparib across subgroups.
|
|
|
|
|
|
|
|
|
|
|
